Flagship biotech Valo Health ends 2024 with mid-stage fail
Valo Health’s diabetic retinopathy drug failed to improve patients’ symptoms in a Phase 2 study, and the company is now on the hunt for a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
